Basic Information
L01EA03
nilotinib
Antineoplastic agents
Therapeutic indication
Nilotinib Accord is indicated for the treatment of:
- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,
- adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,
- paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Overview Summary
Nilotinib Accord is a medicine for treating chronic myelogenous leukaemia (CML) – a blood cancer – in patients who have been newly diagnosed or who cannot take other cancer medicines (including imatinib) because they cause side effects or do not work for them.
Nilotinib Accord is only for patients with a special chromosome in their cancer cells called the Philadelphia chromosome. Nilotinib Accord is used during the chronic phase of the cancer in adults and children, when the condition is developing slowly and the patient has few or no symptoms. It can also be used in adults during the accelerated phase (when the cancer cells are dividing rapidly and the patient may have more symptoms).
Nilotinib Accord contains the active substance nilotinib and is a ‘generic medicine’. This means that Nilotinib Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Nilotinib Accord is Tasigna. For more information on generic medicines, see the question-and-answer document here.
Active Substances (2)
nilotinib
nilotinib
Documents (6)
Nilotinib Accord : EPAR - All authorised presentations
September 11, 2024
AUTHORISED_PRESENTATIONS
Nilotinib Accord : EPAR - Public assessment report
September 11, 2024
CHANGES_SINCE_INITIAL_AUTHORISATION
Nilotinib Accord : EPAR - Medicine overview
September 11, 2024
OVERVIEW_DOCUMENT
CHMP summary of positive opinion for Nilotinib Accord
June 28, 2024
CHANGES_SINCE_INITIAL_AUTHORISATION
Nilotinib Accord : EPAR - Procedural steps taken and scientific information after the authorisation
April 23, 2025
CHANGES_SINCE_INITIAL_AUTHORISATION
Nilotinib Accord : EPAR - Product information
September 11, 2024
DRUG_PRODUCT_INFORMATION
Overview Q&A (7)
Question
How is Nilotinib Accord used?
Answer
Nilotinib Accord can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of CML.
The medicine is available as capsules to be taken twice a day on an empty stomach. Treatment can continue for as long as the patient benefits from it. Adults whose CML is well controlled may stop treatment but should have regular tests to check that the disease has not started to come back.
For more information about using Nilotinib Accord, see the package leaflet or contact your doctor or pharmacist.
Question
How does Nilotinib Accord work?
Answer
The active substance in Nilotinib Accord, nilotinib, belongs to a group of medicines called ‘protein kinase inhibitors’. Nilotinib acts by blocking the protein kinase called BCR-ABL kinase which is produced by leukaemia cells that have the Philadelphia chromosome and causes them to multiply uncontrollably. By blocking BCR-ABL kinase, Nilotinib helps to control the spread of leukaemia cells.
Question
How has Nilotinib Accord been studied?
Answer
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Tasigna, and do not need to be repeated for Nilotinib Accord.
As for every medicine, the company provided studies on the quality of Nilotinib Accord. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.
Question
What are the benefits and risks of Nilotinib Accord?
Answer
Because Nilotinib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Question
Why is Nilotinib Accord authorised in the EU?
Answer
The European Medicines Agency concluded that, in accordance with EU requirements, Nilotinib Accord has been shown to have comparable quality and to be bioequivalent to Tasigna. Therefore, the Agency’s view was that, as for Tasigna, the benefits of Nilotinib Accord outweigh the identified risks and it can be authorised for use in the EU.
Question
What measures are being taken to ensure the safe and effective use of Nilotinib Accord?
Answer
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nilotinib Accord have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Tasigna also apply to Nilotinib Accord where appropriate.
As for all medicines, data on the use of Nilotinib Accord are continuously monitored. Suspected side effects reported with Nilotinib Accord are carefully evaluated and any necessary action taken to protect patients.
Question
Other information about Nilotinib Accord
Answer
Nilotinib Accord received a marketing authorisation valid throughout the EU on 22 August 2024.